NextCure: Stops testing drug candidate in lung, ovarian cancer; shares fall

NextCure

13/07/2020 13:02

** Shares of drug developer  NXTC.O  fall ~11% to $15.9
premarket 
    ** Co says it has decided not to advance its non-small cell
lung cancer and ovarian cancer patient groups into second phase
of 2-stage trial testing its experimental immunotherapy NC318,
based on current clinical response data  urn:newsml:reuters.com:*:nGNX1pGbSg
    ** NC318 is being evaluated against multiple cancer types;
NXTC says it will continue to enroll patients in its head and
neck squamous cell cancer and triple-negative breast cancer
cohorts
    ** Co expects to provide an NC318 clinical data update in Q4
    ** NXTC also says Chief Medical Officer Kevin Heller has
resigned, effective August 4, to pursue a new opportunity
    ** Up to Friday's close, NXTC slumped 68.3% YTD
    

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))